Objective:To evaluate the clinical efficacy of eplerenone in the treatment of patients with mild symptoms systolic heart failure. Methods:A total of 83 patients with systolic heart failure in grade NYHA Ⅱ from February 2013 to December 2015 in our hospital were enrolled in the study

and were divided into 2 group randomly. Patients in the control group（41 cases）were treated with routine anti systolic heart failure

on this basis

the observation group was treated with eplerenone 25 mg/d

if no significant adverse reactions after 1 month

then increased to 50 mg/d. After 6 months of treatment

the symptoms

signs

brain natriuretic peptide（BNP）

plasma transformation growth factor-β1（TGF-β1）

left ventricular shoot ejection fraction（LVEF）

left ventricular contraction end systolic diameter（LVESD）

interventricular septal thickness（IVS）

6 min walking test（6MWT）

quality of life score changes of the two groups before and after treatment were recorded and compared. Results:After receiving different treatments

the plasma levels of BNP and TGF-βin two groups were significantly lower than those before treatment;LVEF

LVESD

IVS

6MWT

quality of life scores were improved compared with those before treatment（P<0.05）. After the treatment

plasma TGF-β（274.08±175.90）pg/m L and BNP level（114.28±39.50）ng/L in observation group was lower than those of control group;the LVEF（49.02±7.41）% and 6MWT [（710.57±158.25） m] were higher

the LVESD [（38.54 ±8.05） mm] and the quality of life scores（41.54 ±10.59） were lower in observation group than in those of control group（P<0.05）. The adverse reaction rate between two groups showed no statistic significant. The total effective rate of the observation group was 69.08%

higher than that of the control group（P<0.05）. Conclusion:As a new high selective aldosterone receptor blocking agent

eplerenone can reduce plasma TGF-β1 level of patients with mild symptoms of systolic heart failure and play a role in improving the heart function and reverse myocardial remodeling on the basis of routine treatment.